These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 31468649)

  • 21. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
    Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
    Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.
    Goldenberg RM; Gilbert JD; Hramiak IM; Woo VC; Zinman B
    Diabetes Obes Metab; 2019 Oct; 21(10):2192-2202. PubMed ID: 31183975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
    Chen Z; Li G
    Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses.
    Zhang Q; Dou J; Lu J
    Diabetes Res Clin Pract; 2014 Sep; 105(3):313-21. PubMed ID: 25015317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of sodium glucose co-transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
    Li K; Xu G
    J Diabetes; 2019 Aug; 11(8):645-655. PubMed ID: 30565398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SGLT inhibitor adjunct therapy in type 1 diabetes.
    McCrimmon RJ; Henry RR
    Diabetologia; 2018 Oct; 61(10):2126-2133. PubMed ID: 30132030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis.
    Tsapas A; Karagiannis T; Kakotrichi P; Avgerinos I; Mantsiou C; Tousinas G; Manolopoulos A; Liakos A; Malandris K; Matthews DR; Bekiari E
    Diabetes Obes Metab; 2021 Sep; 23(9):2116-2124. PubMed ID: 34047443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systematic literature review and Bayesian network meta-analysis of randomized controlled trials.
    Azharuddin M; Adil M; Ghosh P; Sharma M
    Diabetes Res Clin Pract; 2018 Dec; 146():180-190. PubMed ID: 30389620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of metformin and sodium-glucose co-transporter-2 inhibitors in adults with type1 diabetes: A systematic review and network meta-analysis.
    Zhang Q; Wu Y; Lu Y; Fei X
    Rev Clin Esp (Barc); 2020; 220(1):8-21. PubMed ID: 31694774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
    Mishriky BM; Tanenberg RJ; Sewell KA; Cummings DM
    Diabetes Metab; 2018 Mar; 44(2):112-120. PubMed ID: 29477373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials.
    Shi FH; Li H; Shen L; Fu JJ; Ma J; Gu ZC; Lin HW
    Diabetes Obes Metab; 2021 Sep; 23(9):2125-2136. PubMed ID: 34048142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis.
    Lorenzi M; Ploug UJ; Langer J; Skovgaard R; Zoratti M; Jansen J
    Diabetes Ther; 2017 Feb; 8(1):85-99. PubMed ID: 27995594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.
    Li J; Gong Y; Li C; Lu Y; Liu Y; Shao Y
    Medicine (Baltimore); 2017 Jul; 96(27):e7201. PubMed ID: 28682870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.
    Yamada T; Shojima N; Noma H; Yamauchi T; Kadowaki T
    Diabetes Obes Metab; 2018 Jul; 20(7):1755-1761. PubMed ID: 29451721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a meta-analysis.
    Liu C; Wu D; Zheng X; Li P; Li L
    Diabetes Technol Ther; 2015 Feb; 17(2):142-8. PubMed ID: 25369141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetes.
    Siegmund T; Ampudia-Blasco FJ; Schnell O
    Diabetes Res Clin Pract; 2020 Apr; 162():108131. PubMed ID: 32234505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular and metabolic effects of metformin added to insulin therapy in patients with type 1 diabetes: A systematic review and meta-analysis.
    Liu YS; Chen CN; Chen ZG; Peng Y; Lin XP; Xu LL
    Diabetes Metab Res Rev; 2020 Sep; 36(6):e3334. PubMed ID: 32390336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Kawalec P; Mikrut A; Łopuch S
    Diabetes Metab Res Rev; 2014 May; 30(4):269-83. PubMed ID: 24829965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review.
    Hropot T; Battelino T; Dovc K
    Horm Res Paediatr; 2023; 96(6):620-630. PubMed ID: 36279850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.